Date: Monday, October 22, 2018
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
We performed a retrospective cohort study of patients with prevalent RA and cancer seen at MD Anderson Cancer Center between 2002 and 2014. Cancer patients were identified from the institutional tumor registry and RA patients were identified through ICD-9 codes and verified by chart review. Patients were followed until 2016 to assess overall survival (OS). We built Cox Proportional Hazard regression models using bDMARD therapy as a time-varying covariate.
We identified 431 patients with RA of which 111 received bDMARDs at various times after a cancer diagnosis. Of these 111 patients, 60 received bDMARDs prior to the cancer diagnosis and remained on bDMARDs following the cancer diagnosis. In a multivariable model stratified by tumor type and stage and after adjusting for age at diagnosis, OS in patients that received tumor necrosis factor (TNF) inhibitors was compared to patients who never received bDMARDs with a hazard ratio (HR) of 0.67 (95% confidence interval (CI), 0.31, 1.44). Patients who received non-TNF bDMARDs had
We did not observe any statistically significant differences in OS between those that received bDMARDs and those that did not in patients with RA and cancer. More research is necessary to evaluate the effects of
To cite this abstract in AMA style:Pundole X, Zamora N, Siddhanamatha H, Tayar J, Leung CH, Lin H, Suarez-Almazor M. Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/time-dependent-effect-of-biologic-therapy-on-overall-survival-in-patients-with-rheumatoid-arthritis-and-cancer/. Accessed November 29, 2022.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-dependent-effect-of-biologic-therapy-on-overall-survival-in-patients-with-rheumatoid-arthritis-and-cancer/